SUBSCRIBE: eNewsletter
Marked by muscle weakness that begins early in life, periodic paralysis renders patients immobile in episodes that last anywhere from hours to days.
Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.
The regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.
The genomic revolution has led to increasing opportunities to address complex neurodevelopmental conditions, taking a genetics-first approach.
The profound consequences of the results guide decisions about testing. Who should be tested? And, just as important, who should not?
In this podcast, Heidi Moawad, MD interviews Cesar Ochoa-Lubinoff, MD, MPH, FAAP, about recent encouraging clinical trial results in patients with Angelman syndrome.
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
EEG and brain MRI findings are normal—what do you suspect?
Are you up-to-date on recent guidelines for the management of agitation, anxiety, apathy, psychosis, and sleep disorders in patients with Huntington disease? Take this brief quiz to find out.
Some good news about Huntington disease: most of the behavioral symptoms can be managed with treatments developed for other conditions.
What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
